Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
Boston Scientific will acquire the Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation through its Jan. 19 purchase of Atritech for up to $375 million.
More from Archive
More from Medtech Insight
• By
Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.
• By
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
• By
Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.